This is of great clinical relevance, as it indicates the ability of irinotecan to eradicate central nervous system (CNS) infiltration; CNS leukemia involvement is common in MLL-rearranged infant ALL and represents an adverse prognostic factor. Here, KMT2A is linked to leukemia.